Blood Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Myelodysplastic Syndrome
Lorus Therapeutics announces the initiation of a clinical trial of GTI-2040 in acute leukemia and myelodysplastic syndrome
July 5th, 2007
Lorus Therapeutics Inc. ("Lorus") (TSX: LOR; AMEX: LRP), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, announced that enrolment is underway in a new clinical trial in patients with acute leukemia and myelodysplastic syndrome (MDS). The clinical study is designed to evaluate the safety and activity of GTI-2040 as a single agent for acute leukemia and MDS using a novel treatment schedule. The effect on leukemic blasts and blood count recovery will be assessed as part of a detailed investigation of the pharmacodynamic and pharmacokinetic effects, dose-response relationships and...
Source: Blood Weekly (2007-07-05)
|
